犬异位性皮肤炎市场机会、成长动力、产业趋势分析与预测 2025 - 2034

Canine Atopic Dermatitis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年01月09日 | 出版商:

Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024 年全球犬异位性皮肤炎市场价值为 14 亿美元，预计 2025 年至 2034 年期间将以 8.9% 的强劲复合年增长率扩张。宠物主人对宠物的健康越来越关注，导致对先进的兽医皮肤病治疗的需求激增。随着宠物护理的不断发展，市场正在向更有效、更专业的治疗转变，这进一步推动了宠物护理的扩张。此外，将宠物人性化并将其视为家庭成员的全球趋势正在推动市场成长。这些因素共同导致对能够持久缓解病情的药物、诊断和治疗的需求大幅增加。

兽医学的不断进步也在市场发展中发挥着至关重要的作用。单株抗体等创新治疗方法以及更新、更安全的疗法正在获得广泛认可。这些治疗方法因其缓解搔痒和发炎（犬异位性皮肤炎的主要症状）的有效性而受到特别讚赏。随着这些疗法的不断改进，其需求预计会增加，这将进一步加速市场成长。值得注意的是，研发活动不断增加，不断推出突破性的解决方案，为市场持续成功奠定基础。

市场范围
起始年份	2024
预测年份	2025-2034
起始值	14亿美元
预测值	32亿美元
复合年增长率	8.9％

市场按产品类型细分，包括糖皮质激素、抗组织胺、免疫抑制剂、单株抗体和其他疗法。糖皮质激素占据市场主导地位，2024 年价值为 4.771 亿美元。儘管出现了单株抗体和口服 JAK 抑制剂等更新、更昂贵的治疗方法，但糖皮质激素由于其有效性、可负担性和广泛可用性仍然是一种受欢迎的选择。这种可近性使得它们在那些可能无法轻易获得先进兽医护理的地区特别有用。

市场根据给药途径进一步划分，包括口服、外用和注射治疗。 2024 年，口服药物占据市场主导地位，占有 47.2% 的份额。口服治疗通常受到宠物主人的青睐，因为其易于使用，可以增强对规定治疗方案的依从性。这些疗法可以快速缓解搔痒和发炎等症状，通常在几小时到几天内就能见效。

美国犬异位性皮肤炎市场价值在 2024 年为 5.28 亿美元，预计到 2034 年将达到 12 亿美元。先进诊断工具和疗法的采用，加上主要行业参与者提供创新解决方案，预计将维持美国市场的成长。随着宠物主人对宠物状况的了解越来越多且越来越关心，对有效治疗方案的需求也将大幅增加。

The Global Canine Atopic Dermatitis Market was valued at USD 1.4 billion in 2024 and is projected to expand at a robust CAGR of 8.9% from 2025 to 2034. This surge in market growth is driven by an increasing number of dogs diagnosed with atopic dermatitis and a growing focus on the health and well-being of companion animals. Pet owners are becoming more vigilant about their pets' wellness, leading to a spike in demand for advanced veterinary dermatology treatments. As pet care continues to evolve, the market is witnessing a shift towards more effective and specialized treatments, which is further driving the expansion. Additionally, the global trend of humanizing pets and treating them like family members is fueling market growth. These factors collectively contribute to a significant boost in demand for medications, diagnostics, and treatments that can offer lasting relief from the condition.

The ongoing advancements in veterinary medicine are also playing a crucial role in market progression. The availability of innovative treatments such as monoclonal antibodies and newer, safer therapies is gaining widespread acceptance. These treatments are particularly appreciated for their effectiveness in alleviating itching and inflammation, which are the primary symptoms of canine atopic dermatitis. As these therapies continue to improve, their demand is expected to increase, and this will further accelerate market growth. Notably, there has been a rise in research and development activities that continue to introduce groundbreaking solutions, positioning the market for continued success.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$1.4 Billion
Forecast Value	$3.2 Billion
CAGR	8.9%

The market is segmented by product type, including glucocorticoids, antihistamines, immunosuppressants, monoclonal antibodies, and other therapies. Glucocorticoids dominated the market, valued at USD 477.1 million in 2024. Medications such as prednisone and dexamethasone are commonly used in treating severe or acute cases of atopic dermatitis, providing rapid relief from inflammation. Despite the arrival of newer, costlier treatments like monoclonal antibodies and oral JAK inhibitors, glucocorticoids remain a popular option due to their effectiveness, affordability, and widespread availability. This accessibility makes them especially useful in regions where advanced veterinary care might not be readily available.

The market is further divided by route of administration, encompassing oral, topical, and injectable treatments. The oral segment led the market in 2024, holding a 47.2% share. Oral treatments are often preferred by pet owners due to their ease of use, which enhances adherence to prescribed treatment regimens. These therapies offer quick relief from symptoms such as itching and inflammation, often showing results within a few hours to days.

The U.S. canine atopic dermatitis market, valued at USD 528 million in 2024, is expected to reach USD 1.2 billion by 2034. The U.S. continues to hold a prominent position in the global market, driven by a rise in awareness regarding pet healthcare and a significant increase in the number of dogs suffering from atopic dermatitis. The adoption of advanced diagnostic tools and therapies, coupled with the presence of key industry players offering innovative solutions, is expected to sustain the growth of the U.S. market. As pet owners become more knowledgeable and concerned about their pets' conditions, the demand for effective treatment options is set to rise substantially.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising pet ownership and humanization of pets
  - 3.2.1.2 Increased awareness of skin disorders and advanced treatment options
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Side effects of few medications
  - 3.2.2.2 Off-label use of human drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Glucocorticoids
5.3 Antihistamines
5.4 Immunosuppressants
5.5 mAbs
5.6 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Topical
6.4 Injectable

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 Retail pharmacies
7.3 Veterinary hospital pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE